YON E Health raises €250K to bring data-driven insight to vaginal health
Developing a smart device that could change how women monitor vaginal health and fertility.
Femtech start-up YON E Health has raised €250,000 in pre-seed funding, led by PMK-Group, to develop a smart device that could change how women monitor vaginal health and fertility.
Founded by Roswitha Verwer, the Amsterdam-based company is tackling one of healthcare’s blind spots: the lack of accessible, real-time data on vaginal wellbeing. Its first product, a sensor-based medical device, continuously measures vaginal pH and basal body temperature - two biomarkers critical for fertility tracking, infection detection, and hormonal health.
“When I started YON E, I was told vaginal health was too taboo, too complex, and too ‘niche’ for innovation and investment,” said Verwer, YON E Health’s founder and CEO.
“That’s what motivated and pushed me even more. For too long, women have had to guess, self-diagnose, or wait until they show symptoms and something goes wrong with their health. We’re changing that, turning silence into data women can actually use.”
A neglected frontier in women’s health
Despite affecting half the global population, women’s health remains deeply underfunded. Fewer than 1% of global medical research funds target female-specific conditions, and in 2024 only 2.3% of venture capital went to startups founded by women. This funding gap has slowed innovation in areas such as fertility, menopause, and vaginal health - fields long sidelined by stigma and lack of data.
YON E Health’s approach is rooted in closing that evidence gap. Vaginal pH imbalance can indicate a range of issues, from bacterial vaginosis and yeast infections to shifts in hormones or fertility. Current at-home pH tests rely on one-off paper strips used reactively, after symptoms appear. The company’s device aims to make this process continuous and preventive, integrating real-time biosensor readings into a digital health platform.
“Our technology bridges the gap between research and reality,” said Dr. Muskaan Bhan, YON E Health’s Chief Clinical Officer.
“Vaginal health isn’t a luxury; it’s a foundation of overall wellbeing. We’re empowering women globally with clinical-grade insights that can prevent complications before they start.”
Backed by medical expertise
The funding round was led by PMK-Group, an accelerator for disruptive health technologies headed by Dr. Peter M. Kovacs, a gynecologist and clinical researcher who has built one of Eastern Europe’s first private ecosystems for women’s health innovation.
“YON E Health is addressing an area that’s both underserved and scientifically critical,” said Kovacs.
“Their approach—combining biosensor technology, clinical expertise, and user empathy—represents the future of proactive care in women’s health.”
Additional support came from UniPrisma Venture Studio, led by Károly Szántó and Thijmen Meijer, who advised on the deal structure, and Matias Toye, founder of Oyster Shield and Dilicheck, who contributed M&A and fundraising expertise.
The €250K pre-seed will allow YON E Health to prepare for medical trials, a key step toward both regulatory approval and consumer rollout.
A global, cross-disciplinary team
Operating across Amsterdam, Budapest, London, Texas, Boston, and Madrid, YON E Health brings together engineers, clinicians, and entrepreneurs united by a mission to make vaginal health measurable and manageable. Its tagline - “turning silence into data” sums up how it aims to transform overlooked biological signals into actionable insights.